Overview

Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effectiveness and safety of zoledronic acid with alendronate in the prevention of bone loss after organ transplantation. Zoledronic acid is given as a single intravenous infusion. Alendronate is given as a weekly pill. Both are expected to be very effective, but it is not known which one will work best.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Columbia University
Collaborator:
Novartis Pharmaceuticals
Treatments:
Alendronate
Diphosphonates
Zoledronic Acid